CareDx disclosed validation results for AlloHeme, its allogeneic hematopoietic cell transplant (HCT) surveillance cfDNA assay, from the observational ACROBAT study: sensitivity 85%, specificity 92%, and a median 41‑day lead time to clinical relapse versus standard-of-care testing. CareDx said these metrics outperformed typical bone marrow biopsy sensitivity and support a commercial launch next year pending publication and rollout preparations. John Hanna, CareDx CEO, said the company will publish ACROBAT data and build commercialization infrastructure to introduce the assay into transplant surveillance workflows. Investigators noted protocol compliance affected some false negatives; overall, presenters emphasized the potential of blood-based surveillance to shift monitoring paradigms after allogeneic HCT.